13544-07-5

Basic information

• Product Name: methyl (2-nitro-4-trifluorobenzyl)acetate
• Synonyms: methyl (2-nitro-4-trifluorobenzyl)acetate;Methyl2-nitro-4-(trifluoromethyl)phenylacetate;Methyl 2-(2-nitro-4-(trifluoromethyl)phenyl)acetate;2-Nitro-4-(trifluoromethyl)benzeneacetic acid methyl ester
• CAS NO: 13544-07-5
• Molecular Formula: C₁₀H₈F₃NO₄
• Molecular Weight: 263.1700296
• EINECS: 236-914-3
• Product Categories: blocks;Carboxes;FluoroCompounds;NitroCompounds
• Mol File: 13544-07-5.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 277.7°Cat760mmHg
• Flash Point: 121.8°C
• Appearance: /
• Density: 1.402g/cm³
• Vapor Pressure: 0.00444mmHg at 25°C
• Refractive Index: 1.484
• CAS DataBase Reference: methyl (2-nitro-4-trifluorobenzyl)acetate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl (2-nitro-4-trifluorobenzyl)acetate(13544-07-5)
• EPA Substance Registry System: methyl (2-nitro-4-trifluorobenzyl)acetate(13544-07-5)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 13544-07-5(Hazardous Substances Data)

Usage

Uses

Methyl (2-nitro-4-trifluoromethylphenyl)acetate

InChI:InChI=1/C10H8F3NO4/c1-18-9(15)4-6-2-3-7(10(11,12)13)5-8(6)14(16)17/h2-3,5H,4H2,1H3

Upstream product

• 65754-26-9 2-methyl-5-trifluoromethylnitrobenzene 
• 13544-04-2 Ethyl 2-cyano-2-(2-nitro-4-(trifluoromethyl)phenyl)acetate 
• 67-56-1 methanol 
• 1735-91-7 2-(2-nitro-4-(trifluoromethyl)phenyl)acetic acid 
• 121-17-5 2-chloro-3-nitro-5-trifluoromethylbenzene 
• 98-56-6 4-chlorobenzotrifluoride 
• 290825-52-4 dimethyl 2-(2-nitro-4-trifluoromethylphenyl)malonate 

Downstream Products

• 1735-89-3 6-trifluoromethyl-2-indolinone 
• 877766-69-3 3-[1-(2,4-dichlorobenzyl)-6-trifluoromethyl-1H-indazol-3-yl]-propionic acid ethyl ester 
• 877768-45-1 trans-2-[1-(2,4-dichloro-benzyl)-6-trifluoromethyl-1H-indazol-3-yl]-cyclopropanecarboxylic acid 
• 877773-17-6 6-Trifluoromethyl-1H-indazole-3-carboxylic acid methyl ester 
• 877766-37-5 methyl 1-(2,4-dichlorobenzyl)-6-(trifluoromethyl)-1H-indazole-3-carboxylate 
• 877773-19-8 2-(2,4-dichlorobenzyl)-6-trifluoromethyl-2H-indazole-3-carboxylic acid methyl ester 
• 877773-21-2 1-(2,4-dichlorobenzyl)-6-(trifluoromethyl)-1H-indazole-3-carbaldehyde 
• 877768-41-7 3-[1-(2,4-dichlorobenzyl)-6-trifluoromethyl-1H-indazol-3-yl]-oxirane-2-carboxylic acid 
• 877772-09-3 (1-(2,4-dichlorobenzyl)-6-(trifluoromethyl)-1H-indazol-3-yl)methanol 
• 877766-45-5 (E)-3-(1-(2,4-dichlorobenzyl)-6-(trifluoromethyl)-1H-indazol-3-yl)acrylic acid 
• 877768-84-8 H₂-gamendazole 
• 877766-73-9 3-[1-(2,4-dichlorobenzyl)-6-trifluoromethyl-1H-indazol-3-yl]-acrylic acid ethyl ester 
• 877773-31-4 3-[1-(2,4-Dichlorobenzyl)-6-trifluoromethyl-1H-indazol-3-yl]-acrylic acid ethyl ester 
• 877768-95-1 3-[1-(2,4-dichlorobenzyl)-5-trifluoromethyl-1H-indazol-3-yl]-propionic acid 

Relevant articles and documents

PIII/PV=O Catalyzed Cascade Synthesis of N-Functionalized Azaheterocycles

An organocatalytic method for the modular synthesis of diverse N-aryl and N-alkyl azaheterocycles (indoles, oxindoles, benzimidazoles, and quinoxalinediones) is reported. The method employs a small-ring organophosphorus-based catalyst (1,2,2,3,4,4-hexamethylphosphetane P-oxide) and a hydrosilane reductant to drive the conversion of ortho-functionalized nitroarenes into azaheterocycles through sequential intermolecular reductive C?N cross coupling with boronic acids, followed by intramolecular cyclization. This method enables the rapid construction of azaheterocycles from readily available building blocks, including a regiospecific approach to N-substituted benzimidazoles and quinoxalinediones.

Lonidamine analogues and their use in male contraception and cancer treatment

Novel compounds useful for inhibiting spermatogenesis and cancer treatment, and in particular as inhibitors of heat shock proteins and/or elongation factor 1 alpha.

BISARYLUREA DERIVATIVES

The present invention relates to bisarylurea derivatives of formula (I), the use of the compounds of formula (I) as inhibitors of raf-kinase, the use of the compounds of formula (I) for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said pharmaceutical composition to a patient.